Insider Buying: Profound Medical (TSE:PRN) Insider Buys C$83,100.00 in Stock

Profound Medical Corp. (TSE:PRN) insider Richard Ringler Fabian acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was bought at an average price of C$8.31 per share, with a total value of C$83,100.00. Following the completion of the acquisition, the insider directly owned 10,000 shares of the company’s stock, valued at approximately C$83,100. This represents a ∞ increase in their ownership of the stock.

Profound Medical Price Performance

TSE:PRN traded up C$0.18 during midday trading on Thursday, hitting C$8.36. 5,417 shares of the stock were exchanged, compared to its average volume of 15,894. The company has a market capitalization of C$305.47 million, a price-to-earnings ratio of -8.44 and a beta of 1.06. The company has a current ratio of 6.46, a quick ratio of 14.98 and a debt-to-equity ratio of 14.82. Profound Medical Corp. has a one year low of C$5.36 and a one year high of C$12.40. The business has a 50-day moving average price of C$9.70 and a two-hundred day moving average price of C$9.31.

Profound Medical (TSE:PRN) last issued its quarterly earnings results on Thursday, August 6th. The company reported C($0.37) earnings per share (EPS) for the quarter. Profound Medical had a negative net margin of 170.92% and a negative return on equity of 62.45%. The firm had revenue of C$3.53 million for the quarter. Sell-side analysts predict that Profound Medical Corp. will post -1.9000001 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Raymond James Financial upgraded shares of Profound Medical from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, July 27th. Five analysts have rated the stock with a Buy rating, nineteen have given a Moderate Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of C$8.36.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.